PAX5 expression in acute leukemias

Higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia

Enrico Tiacci, Stefano Pileri, Annette Orleth, Roberta Pacini, Alessia Tabarrini, Federica Frenguelli, Arcangelo Liso, Daniela Diverio, Francesco Lo-Coco, Brunangelo Falini

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

The transcription factor PAX5 plays a key role in the commitment of hematopoietic precursors to the B-cell lineage, but Its expression in acute leukemias has not been thoroughly investigated. Hereby, we analyzed routine biopsies from 360 acute leukemias of lymphoid (ALLs) and myeloid (AMLs) origin with a specific anti-PAX5 monoclonal antibody. Blasts from 150 B-cell ALLs showed strong PAX5 nuclear expression, paralleling that of CD79a in the cytoplasm. Conversely, PAX5 was not detected in 50 T-cell ALLs, including 20 cases aberrantly coexpressing CD79a. Among 160 cytogenetically/molecularly characterized AMLs, PAX5 was selectively detected in 15 of 42 cases bearing the t(8;21)/AML1-ETO rearrangement. Real-time reverse transcription-PCR studies in t(8;21)-AML showed a similar up-regulation of PAX5 transcript in all of the 8 tested samples (including 4 cases that were negative at anti-PAX5 immunostaining), suggesting that PAX5 is expressed in t(8;21)-AML more widely than shown by immunohistochemistry. Interestingly, PAX5+ t(8;21)-AML also expressed CD79a and/or CD19 (major transcriptional targets of PAX5 in B-cells) in 10 of 12 evaluable cases. Our results indicate that PAX5 is a more specific marker than CD79a for B-cell ALL diagnosis. Moreover, among AMLs, PAX5 expression selectively clusters with t(8; 21), allowing its immunohistochemical recognition in a proportion of cases, and likely explaining a peculiar biological feature of this subset of myeloid leukemias, i.e. the aberrant expression of B-cell genes.

Original languageEnglish
Pages (from-to)7399-7404
Number of pages6
JournalCancer Research
Volume64
Issue number20
DOIs
Publication statusPublished - Oct 15 2004

Fingerprint

B-Cell Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
PAX5 Transcription Factor
Leukemia
B-Lymphocytes
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Myeloid Leukemia
B-Lymphoid Precursor Cells
Cell Lineage
Reverse Transcription
Cytoplasm
Up-Regulation
Immunohistochemistry
Monoclonal Antibodies
Biopsy
Polymerase Chain Reaction
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

PAX5 expression in acute leukemias : Higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. / Tiacci, Enrico; Pileri, Stefano; Orleth, Annette; Pacini, Roberta; Tabarrini, Alessia; Frenguelli, Federica; Liso, Arcangelo; Diverio, Daniela; Lo-Coco, Francesco; Falini, Brunangelo.

In: Cancer Research, Vol. 64, No. 20, 15.10.2004, p. 7399-7404.

Research output: Contribution to journalArticle

Tiacci, Enrico ; Pileri, Stefano ; Orleth, Annette ; Pacini, Roberta ; Tabarrini, Alessia ; Frenguelli, Federica ; Liso, Arcangelo ; Diverio, Daniela ; Lo-Coco, Francesco ; Falini, Brunangelo. / PAX5 expression in acute leukemias : Higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. In: Cancer Research. 2004 ; Vol. 64, No. 20. pp. 7399-7404.
@article{3d20f472f74a44acadd971c0a04671a4,
title = "PAX5 expression in acute leukemias: Higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia",
abstract = "The transcription factor PAX5 plays a key role in the commitment of hematopoietic precursors to the B-cell lineage, but Its expression in acute leukemias has not been thoroughly investigated. Hereby, we analyzed routine biopsies from 360 acute leukemias of lymphoid (ALLs) and myeloid (AMLs) origin with a specific anti-PAX5 monoclonal antibody. Blasts from 150 B-cell ALLs showed strong PAX5 nuclear expression, paralleling that of CD79a in the cytoplasm. Conversely, PAX5 was not detected in 50 T-cell ALLs, including 20 cases aberrantly coexpressing CD79a. Among 160 cytogenetically/molecularly characterized AMLs, PAX5 was selectively detected in 15 of 42 cases bearing the t(8;21)/AML1-ETO rearrangement. Real-time reverse transcription-PCR studies in t(8;21)-AML showed a similar up-regulation of PAX5 transcript in all of the 8 tested samples (including 4 cases that were negative at anti-PAX5 immunostaining), suggesting that PAX5 is expressed in t(8;21)-AML more widely than shown by immunohistochemistry. Interestingly, PAX5+ t(8;21)-AML also expressed CD79a and/or CD19 (major transcriptional targets of PAX5 in B-cells) in 10 of 12 evaluable cases. Our results indicate that PAX5 is a more specific marker than CD79a for B-cell ALL diagnosis. Moreover, among AMLs, PAX5 expression selectively clusters with t(8; 21), allowing its immunohistochemical recognition in a proportion of cases, and likely explaining a peculiar biological feature of this subset of myeloid leukemias, i.e. the aberrant expression of B-cell genes.",
author = "Enrico Tiacci and Stefano Pileri and Annette Orleth and Roberta Pacini and Alessia Tabarrini and Federica Frenguelli and Arcangelo Liso and Daniela Diverio and Francesco Lo-Coco and Brunangelo Falini",
year = "2004",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-04-1865",
language = "English",
volume = "64",
pages = "7399--7404",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - PAX5 expression in acute leukemias

T2 - Higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia

AU - Tiacci, Enrico

AU - Pileri, Stefano

AU - Orleth, Annette

AU - Pacini, Roberta

AU - Tabarrini, Alessia

AU - Frenguelli, Federica

AU - Liso, Arcangelo

AU - Diverio, Daniela

AU - Lo-Coco, Francesco

AU - Falini, Brunangelo

PY - 2004/10/15

Y1 - 2004/10/15

N2 - The transcription factor PAX5 plays a key role in the commitment of hematopoietic precursors to the B-cell lineage, but Its expression in acute leukemias has not been thoroughly investigated. Hereby, we analyzed routine biopsies from 360 acute leukemias of lymphoid (ALLs) and myeloid (AMLs) origin with a specific anti-PAX5 monoclonal antibody. Blasts from 150 B-cell ALLs showed strong PAX5 nuclear expression, paralleling that of CD79a in the cytoplasm. Conversely, PAX5 was not detected in 50 T-cell ALLs, including 20 cases aberrantly coexpressing CD79a. Among 160 cytogenetically/molecularly characterized AMLs, PAX5 was selectively detected in 15 of 42 cases bearing the t(8;21)/AML1-ETO rearrangement. Real-time reverse transcription-PCR studies in t(8;21)-AML showed a similar up-regulation of PAX5 transcript in all of the 8 tested samples (including 4 cases that were negative at anti-PAX5 immunostaining), suggesting that PAX5 is expressed in t(8;21)-AML more widely than shown by immunohistochemistry. Interestingly, PAX5+ t(8;21)-AML also expressed CD79a and/or CD19 (major transcriptional targets of PAX5 in B-cells) in 10 of 12 evaluable cases. Our results indicate that PAX5 is a more specific marker than CD79a for B-cell ALL diagnosis. Moreover, among AMLs, PAX5 expression selectively clusters with t(8; 21), allowing its immunohistochemical recognition in a proportion of cases, and likely explaining a peculiar biological feature of this subset of myeloid leukemias, i.e. the aberrant expression of B-cell genes.

AB - The transcription factor PAX5 plays a key role in the commitment of hematopoietic precursors to the B-cell lineage, but Its expression in acute leukemias has not been thoroughly investigated. Hereby, we analyzed routine biopsies from 360 acute leukemias of lymphoid (ALLs) and myeloid (AMLs) origin with a specific anti-PAX5 monoclonal antibody. Blasts from 150 B-cell ALLs showed strong PAX5 nuclear expression, paralleling that of CD79a in the cytoplasm. Conversely, PAX5 was not detected in 50 T-cell ALLs, including 20 cases aberrantly coexpressing CD79a. Among 160 cytogenetically/molecularly characterized AMLs, PAX5 was selectively detected in 15 of 42 cases bearing the t(8;21)/AML1-ETO rearrangement. Real-time reverse transcription-PCR studies in t(8;21)-AML showed a similar up-regulation of PAX5 transcript in all of the 8 tested samples (including 4 cases that were negative at anti-PAX5 immunostaining), suggesting that PAX5 is expressed in t(8;21)-AML more widely than shown by immunohistochemistry. Interestingly, PAX5+ t(8;21)-AML also expressed CD79a and/or CD19 (major transcriptional targets of PAX5 in B-cells) in 10 of 12 evaluable cases. Our results indicate that PAX5 is a more specific marker than CD79a for B-cell ALL diagnosis. Moreover, among AMLs, PAX5 expression selectively clusters with t(8; 21), allowing its immunohistochemical recognition in a proportion of cases, and likely explaining a peculiar biological feature of this subset of myeloid leukemias, i.e. the aberrant expression of B-cell genes.

UR - http://www.scopus.com/inward/record.url?scp=5644235305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5644235305&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-1865

DO - 10.1158/0008-5472.CAN-04-1865

M3 - Article

VL - 64

SP - 7399

EP - 7404

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 20

ER -